Pemafibrate, sold under the brand name Parmodia, is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It is developed and marketed by Kowa Pharmaceuticals.
{{Infobox drug | drug_name = | INN = | type = | IUPAC_name = (2R)-2-[3-({1,3-Benzoxazol-2-yl[3-(4-methoxyphenoxy)propyl]amino}methyl)phenoxy]butanoic acid | image = Pemafibrate.svg | image_class = skin-invert-image | width = | alt = | caption =
| pronounce = | tradename = Parmodia | Drugs.com = | MedlinePlus = | DailyMedID = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = Oral | class = | ATCvet = | ATC_prefix = C10 | ATC_suffix = AB12 | ATC_supplemental =
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).